Drugs | Dosing | Comments |
ATRA plus idarubicin[1] | ATRA: 45 mg/m2 per day in two divided doses until complete response. | This is the AIDA protocol that yields a 94 percent remission rate. After three intensive consolidation courses plus maintenance therapy, the event-free survival at 12 years was 69 percent. |
Idarubicin: 12 mg/m2 intravenous push days 2, 4, 6, and 8. | ||
ATRA plus daunorubicin plus cytarabine[2] | ATRA: 45 mg/m2 per day in two divided doses until complete response. | This North American Intergroup regimen had a high complete remission rate of 90 percent. When followed by arsenic trioxide for consolidation, the event-free survival was 80 percent and overall survival 86 percent at three years. Disease-free survival was 90 percent. |
Daunorubicin: 50 mg/m2 intravenous push on each of days 3 through 6 (four doses). | ||
Cytarabine: 200 mg/m2 daily as a continuous infusion for days 3 through 9 (seven days). | ||
ATRA plus arsenic trioxide[3] | ATRA: 45 mg/m2 per day in two divided doses until complete response. | Initial studies demonstrate good results with short follow-up. Yields a >85 percent remission rate. May be an excellent option for patients with low or intermediate risk disease, especially those who are not able to tolerate anthracycline-based therapy. Hydroxyurea, daunorubicin, or gemtuzumab ozogamicin have been added if the WBC count rises dramatically. |
Arsenic trioxide: 0.15 mg/kg per day until complete response. | ||
ATRA plus arsenic trioxide plus gemtuzumab ozogamicin[4] | ATRA: 45 mg/m2 per day in two divided doses until complete response. | Initial study demonstrated a response rate of 92 percent. At a median follow-up of 24 months, the estimated three-year survival rate was 85 percent. Disease-related complications resulted in an early death rate of 8 percent. |
Arsenic trioxide: 0.15 mg/kg per day beginning on day 1 with the ATRA and continuing until complete response. | ||
Gemtuzumab ozogamicin: 9 mg/m2 on day 1 for high risk patients (defined as white count ≥10x109/L). |
Do you want to add Medilib to your home screen?